GlassScriptPhysician profile
Sijil Patel
NPI 1285370486
$597.22
in general payments reported to CMS, 2019-2025
13 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.95 · 2023: $36.61 · 2024: $233 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $567.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $190.46 | 2024-2025 | |
| Janssen Biotech, INC. | $52.21 | 2025 | |
| Pfizer INC. | $51.64 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $45.80 | 2025 | Austedo Xr |
| Genzyme Corporation | $45.06 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $33.78 | 2024 | Ingrezza |
| Ucb, INC. | $31.24 | 2024 | Briviact |
| Takeda Pharmaceuticals U.S.A., INC. | $29.95 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $29.67 | 2024 | Dysport |
| Argenx US, INC. | $28.80 | 2024 | Vyvgart Hytrulo |
| Grifols USA, LLC | $26.28 | 2025 | Gamunex-C |
| Csl Behring | $19.03 | 2024 | Hizentra |
| Abbvie INC. | $13.30 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sijil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.